ArticleOncogene2007
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- Pembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long‑term survival: A case report and literature review.Oncology letters · 2025Article
- Malignant peritoneal mesothelioma interactome with 417 novel protein-protein interactions.BJC reports · 2024Article
- Article
- Normal mesothelial cell lines newly derived from human pleural biopsy explants.American journal of physiology. Lung cellular and molecular physiology · 2020Article
- Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.Therapeutic advances in medical oncology · 2020Review
- Establishment and characterization of CRISPR/Cas9-mediated NF2Cancer science · 2019Article
- Crosstalk Between Apoptosis and Autophagy Is Regulated by the Arginylated BiP/Beclin-1/p62 Complex.Molecular cancer research : MCR · 2018Article
- Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites.ACG case reports journal · 2018Article
- Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.Scientific reports · 2017Article
- Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.Genes & cancer · 2016Review
- The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Article
- Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53.Molecular cancer research : MCR · 2015Article
- Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.European respiratory review : an official journal of the European Respiratory Society · 2015Review
- Article
- Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.British journal of pharmacology · 2012Review
- Article
- Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.Cancer chemotherapy and pharmacology · 2010Article
- FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis.Cell cycle (Georgetown, Tex.) · 2009Review
- Making the case for molecular staging of malignant pleural mesothelioma.Seminars in thoracic and cardiovascular surgery · 2009Review
- Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients.BMC medical genomics · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant mesothelioma is an aggressive neoplastic proliferation derived from cells lining serosal membranes. The biological and clinical characteristics of epithelial type malignant mesothelioma are distinct from those of biphasic and sarcomatous type tumors. The goal of our study was to examine the molecular basis for this distinction. Microarray analysis confirmed that the molecular signatures of epithelial and biphasic histologic subtypes were distinct. Among the differentially expressed functional gene categories was the ubiquitin-proteasome pathway, which was upregulated in biphasic tumors. Cytotoxicity experiments indicated that 211H cells derived from biphasic tumors were synergistically sensitive to sequential combination regimens containing the proteasome inhibitor bortezomib and oxaliplatin. The mechanism of this synergistic response, which was not detected in cells of epithelial tumor origin, was apoptosis. Together, our results identify the ubiquitin-proteasome pathway as a biomarker of poor prognosis biphasic peritoneal mesothelioma tumors and suggest that proteasome inhibitors could increase the effectiveness of cytotoxic chemotherapy in this subset of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.